The New American – March 17, 2014 By Rebecca Terrell Dateline: Ontario, Canada. Eighteen-year-old Brennan McCartney visited his doctor for a chest cold and, despite…
It is difficult to absorb the recent data released by the Agency for Healthcare Research and Quality, AHRQ, and not come to the conclusion that this startling information represents the never-ending harm initiated by the idiotic psychiatric theories of Harvard child psychiatrist, Dr. Joseph Biederman.
In order to fully grasp just how outrageous the data are, one first must remember that the now disgraced and marginalized Biederman is credited with being the ring leader for diagnosing the alleged bipolar disorder in very young children.
Has the motion picture industry become the newest outlet for pharmaceutical product advertising? And as part of that promotion will the viewing audience understand that Seroquel, one of the most powerful mind-altering drugs in psychiatry’s arsenal, has been dubbed the pharmaceutical equivalent of a chemical lobotomy? The recently released Silver Linings Playbook, for example, in an apparent attempt to legitimize the alleged mental illness bipolar disorder, and also convince the audience that psychiatric medication is the necessary treatment, not only specifically mentions Seroquel but also provides a close up of the actual pill.
Johnson & Johnson, the company that makes the antipsychotic drug Risperdal, has tentatively agreed to a settlement of $2.2 billion to resolve a federal investigation into the company’s marketing practices.
In his book Psychiatryland, psychiatrist Phillip Sinaikin recounts reading a scientific article in which it was debated whether a three-year-old girl who ran out into traffic had oppositional-defiant disorder or bipolar disorder, the latter marked by “grandiose delusions” that she was special and cars could not harm her.1
How did the once modest medical specialty of child psychiatry become the aggressive “pediatric psychopharmacology” that finds ADHD, pediatric conduct disorder, depression, bipolar disorder, oppositional defiant disorder, mood disorders, obsessive-compulsive disorders, mixed manias, social phobia, anxiety, sleep disorders, borderline disorders, assorted “spectrum” disorders, irritability, aggression, pervasive development disorders, personality disorders, and even schizophrenia under every rock? And how did this branch of psychiatry come to find the answer to the “psychopathologies” in the name of the discipline itself: pediatric psychopharmacology? Just good marketing. Pharma is wooing the pediatric patient because that’s where the money is. Just like country and western songs about finding love where you can when there is no love to be found at home. Pharma has stopped finding “love” in the form of the new blockbuster drugs that catapulted it through the 1990s and 2000s. According to the Wall Street Journal, new drugs made Pharma only $4.3 billion in 2010 compared with $11.8 billion in 2005—a two-thirds drop